leptoprol 5mg implant in pre-filled syringe
1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - leuprorelin acetate - implant - leuprorelin acetate 5 mg - endocrine therapy
prostap 3 dcs 11.25 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe
pco manufacturing ltd. - leuprorelin acetate - powder and solvent for prolonged-release suspension for injection in pre-filled syringe - 11.25 milligram(s) - leuprorelin
eligard 45 mg powder and solvent for solution for injection
astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 45 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
eligard 22.5 mg, powder and solvent for solution for injection
astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
eligard 7.5 mg powder and solvent for solution for injection
astellas pharma co. ltd - leuprorelin acetate - powder and solvent for solution for injection - 7.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
eligard 22.5 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 22.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
eligard 45 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 45 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
eligard 7.5 mg
kamada ltd, israel - leuprorelin acetate - powder and solvent for solution for injection - leuprorelin acetate 7.5 mg - eligard is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
lutrate 3 month depot 22.5 mg powder and solvent for prolonged-release suspension for injection
gp-pharm, s.a. - leuprorelin acetate - powder and solvent for prolonged-release suspension for injection - 22.5 milligram(s) - gonadotropin releasing hormone analogues; leuprorelin
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostatic neoplasms - endocrine therapy - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.